
SeaStar Medical Holding Corporation (ICU) Stock Ticker
Market factors today
Unlock the full ICU picture
About SeaStar Medical Holding Corporation
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
ICU stock facts
| Ticker symbol | ICU |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $9.7M |
| CEO | Eric Schlorff |
| Employees | 18 |
| Headquarters | Denver, CO, US |
| IPO date | 2021-03-18 |
| Website | www.seastarmedical.com |
What you can see for ICU on Tickr
Live ICU price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ICU report.
Rankings
FAQ
What is the ticker symbol for SeaStar Medical Holding Corporation?
The ticker symbol for SeaStar Medical Holding Corporation is ICU, listed on the NASDAQ Capital Market.
What is ICU?
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a…